COR Therapeutics used biotechnology to discover, develop, and market innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, including the market-leading anti-platelet cardiovascular product, INTEGRILIN(R) (eptifibatide) Injection. In 2001, COR was acquired by Millennium Pharmaceuticals, which currently operates as Takeda Oncology (TKPYY – OTC).